JP Morgan Chase’s Seres Therapeutics MCRB Stock Holding History

JP Morgan Chase’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2,255	Closed	-$929K	–	6495
2021 Q1	$929K	Buy	+2,255	New	+$1.04M	﹤0.01%	4283

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

JP Morgan Chase's MCRB Position: Q4 2025 in Review

JP Morgan Chase sold out of Seres Therapeutics (MCRB) in Q4 2025, closing a stake of 65 shares — an estimated $1.25K sold.

JP Morgan Chase first reported a position in MCRB in Q2 2015 and held it in 42 quarters. The position peaked at $7.12M in Q4 2015. 36 funds tracked by Wall St. Rank hold MCRB as of Q4 2025.

JP Morgan Chase reported no remaining Seres Therapeutics position as of Q4 2025 after selling out during the quarter.
JP Morgan Chase sold 65 Seres Therapeutics shares in Q4 2025, an estimated $1.25K.
JP Morgan Chase first reported a position in Seres Therapeutics in Q2 2015 and held it in 42 quarters.
JP Morgan Chase's Seres Therapeutics position peaked at $7.12M in Q4 2015.
36 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2025.

Based on JP Morgan Chase's 13F filing for Q4 2025, filed 11 Feb 2026.